Compare VLN & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLN | CGEN |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.8M | 191.1M |
| IPO Year | 2021 | 2001 |
| Metric | VLN | CGEN |
|---|---|---|
| Price | $1.72 | $2.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 784.5K | 300.6K |
| Earning Date | 05-13-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.37 | N/A |
| Revenue Next Year | $16.99 | $75.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.30 |
| 52 Week High | $3.71 | $3.24 |
| Indicator | VLN | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 53.27 |
| Support Level | $1.40 | $2.54 |
| Resistance Level | $1.76 | $2.99 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 7.14 | 44.88 |
Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.